Jacobs Levy Equity Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Jacobs Levy Equity Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.08M	Buy	1,168,681 +460,253	+65%	+$3.55M	0.03%	340
2025 Q4	$6.25M	Buy	708,428 +599,818	+552%	+$3.3M	0.02%	366
2025 Q3	$542K	Sell	108,610 -57,383	-35%	-$266K	﹤0.01%	809
2025 Q2	$783K	Sell	165,993 -108,300	-39%	-$474K	﹤0.01%	805
2025 Q1	$1.26M	Sell	274,293 -196,433	-42%	-$916K	0.01%	767
2024 Q4	$2.25M	Sell	470,726 -959,807	-67%	-$4.61M	0.01%	572
2024 Q3	$6.71M	Sell	1,430,533 -55,729	-4%	-$299K	0.03%	389
2024 Q2	$8.4M	Buy	1,486,262 +66,702	+5%	+$345K	0.03%	360
2024 Q1	$5.83M	Sell	1,419,560 -10,290	-0.7%	-$41.2K	0.03%	396
2023 Q4	$6.03M	Buy	1,429,850 +463,994	+48%	+$1.87M	0.03%	393
2023 Q3	$4.17M	Buy	965,856 +156,896	+19%	+$872K	0.02%	410
2023 Q2	$5.33M	Sell	808,960 -87,547	-10%	-$561K	0.03%	378
2023 Q1	$6.09M	Buy	896,507 +46,162	+5%	+$325K	0.04%	360
2022 Q4	$6.28M	Sell	850,345 -5,625	-0.7%	-$54.8K	0.04%	354
2022 Q3	$8.46M	Sell	855,970 -175,525	-17%	-$1.85M	0.07%	290
2022 Q2	$11.2M	Buy	1,031,495 +950,812	+1,178%	+$9.85M	0.09%	259
2022 Q1	$913K	Buy	+80,683	New	+$1.06M	0.01%	766
2021 Q4	–	Sell	-87,493	Closed	-$1.5M	–	1080
2021 Q3	$1.5M	Sell	87,493 -134,141	-61%	-$2.35M	0.01%	671
2021 Q2	$4.77M	Sell	221,634 -486,854	-69%	-$8.71M	0.03%	444
2021 Q1	$10.6M	Sell	708,488 -42,951	-6%	-$695K	0.08%	283
2020 Q4	$9.87M	Buy	751,439 +303,295	+68%	+$3.65M	0.09%	265
2020 Q3	$4.33M	Buy	+448,144	New	+$4.79M	0.04%	374
2019 Q2	–	Sell	-12,900	Closed	-$237K	–	1034
2019 Q1	$237K	Sell	12,900 -84,635	-87%	-$1.93M	﹤0.01%	872
2018 Q4	$2.55M	Buy	97,535 +61,910	+174%	+$1.46M	0.04%	407
2018 Q3	$818K	Sell	35,625 -5,675	-14%	-$116K	0.01%	682
2018 Q2	$787K	Buy	41,300 +6,410	+18%	+$107K	0.01%	714
2018 Q1	$588K	Buy	34,890 +12,400	+55%	+$208K	0.01%	752
2017 Q4	$342K	Buy	+22,490	New	+$334K	0.01%	829

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's VNDA Position: Q1 2026 in Review

Jacobs Levy Equity Management increased its Vanda Pharmaceuticals (VNDA) stake by 65% in Q1 2026, buying an estimated $3.55M and bringing the position to 1,168,681 shares worth $8.08M. The position accounts for 0.03% of the portfolio, ranked #340.

Jacobs Levy Equity Management first reported a position in VNDA in Q4 2017 and has held it in 28 quarters since. The position peaked at $11.2M in Q2 2022. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

Jacobs Levy Equity Management held 1,168,681 shares of Vanda Pharmaceuticals worth $8.08M as of Q1 2026.
Jacobs Levy Equity Management bought 460,253 Vanda Pharmaceuticals shares in Q1 2026, an estimated $3.55M.
Vanda Pharmaceuticals made up 0.03% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #340 holding.
Jacobs Levy Equity Management first reported a position in Vanda Pharmaceuticals in Q4 2017 and has held it in 28 quarters since.
Jacobs Levy Equity Management's Vanda Pharmaceuticals position peaked at $11.2M in Q2 2022.
170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.